Haematologic Malignancies
Nurix Therapeutics Inc. focuses on clinical research in relapsed/refractory B-cell malignancies, with particular attention to chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Relapsed/refractory B-cell malignancies
The sponsor’s active trials are directed toward patients with disease that has progressed after prior treatment, reflecting a strong therapeutic interest in difficult-to-treat blood cancers.
B-cell Targeted Therapy
Its research portfolio includes therapies aimed at B-cell disease biology, especially in settings where prior exposure to Bruton’s tyrosine kinase inhibitors and BCL-2 inhibitors has limited treatment options.
- Bruton’s tyrosine kinase inhibition
- BCL-2 pathway targeting
- Previously treated CLL/SLL
This area of interest centers on patients with resistant or recurrent disease requiring new approaches within targeted oncology.
Refractory Disease Management
The sponsor is engaged in studies for refractory haematologic cancers, with emphasis on populations that have received multiple prior therapies and remain in need of additional treatment options.
- Previously treated adults
- Multi-line therapy settings
- Advanced-stage B-cell disease
Clinical activity in this area highlights a therapeutic focus on persistent lymphoid malignancies and treatment-resistant disease states.
